MedPath

Study of Efficacy of WELT-IP in Insomnia (WCTP-I-B-01)

Not Applicable
Completed
Conditions
Insomnia
Registration Number
NCT05822999
Lead Sponsor
WELT corp
Brief Summary

The purpose of the study was to determine safety and efficacy of WELT-IP in adult insomnia patients. WELT-IP is a cognitive behavioral therapy for insomnia (CBT-I) based digital therapeutics.

Detailed Description

This was a randomized, double-blinded, sham-controlled trial. Overall, 52 subjects were randomized into the following groups:

* WELT-IP group: WELT-IP (insomnia digital therapeutics) use

* Control group: sham app use Subjects in both groups continued to receive their clinician-directed standard-of-care treatment for insomnia, if applicable, including pharmacotherapy. Subjects were randomized and in WELT-IP group used WELT-IP and subjects in control group used a sham for a period of 6 weeks.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • DSM-5 insomnia patient
  • ISI of 8 or above
  • for 7 days before baseline visit (Visit 2), completing sleep diary for more than 4 days in the guidelines
  • capable of using mobile device and application
Exclusion Criteria
  • currently on non-pharmacological treatment for insomnia (ex. CBT-I, light therapy, oriental therapy for insomnia)
  • sleep disorders diagnosis other than insomnia (ex. Obstructive sleep apnea, sleep behavior problem, restless leg syndrome)
  • progressive and active medical conditions
  • received continuous psychotherapy such as CBT, motivational enhancement therapy, psychotherapy, and psychoanalysis in the past 3 months
  • major psychiatric illness as assessed through MINI
  • suicide risk as assessed through C-SSRS
  • having occupational risk due to sleep restriction
  • shift workers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from baseline (before using) to week 8 (after 6 weeks of using) of Insomnia severity index (ISI)8 weeks

Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.

Secondary Outcome Measures
NameTimeMethod
Change from baseline (before using) to week 8 (after 6 weeks of using) of Dysfunctional beliefs and attitudes about sleep-16 (DBAS-16)8 weeks

Dysfunctional beliefs and attitudes about sleep-16 has sixteen questions. Responses can range from 0 to 10, where higher scores indicate more irrational belief and attitude toward sleep.

Change from baseline (before using) to week 8 (after 6 weeks of using) of Pittsburgh sleep quality index (PSQI)8 weeks

Pittsburgh sleep quality index has ten questions. Total score ranges from 0 to 21, where higher scores indicate lower quality of sleep.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep efficiency (SE)8 weeks

Sleep efficiency is calculated as percentage of Total sleep time/time in bed.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep quality (SQ)8 weeks

Sleep quality ranges from 1 to 5, where higher score indicates better quality of sleep.

Change from baseline (before using) to week 14 (after 6 weeks from close out visit) of Insomnia severity index (ISI) for WELT-IP group14 weeks

Insomnia severity index has seven questions. Total score ranges from 0 to 28, where higher scores indicate more acute symptoms of insomnia.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Sleep onset latency (SOL)8 weeks

Sleep onset latency is evaluated as the time it takes a person to fall asleep after going to bed.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Wake after sleep onset (WASO)8 weeks

Wake after sleep onset is calculated as the total number of minutes that a person is awake after initially falling asleep.

Change from baseline (before using) to week 8 (after 6 weeks of using) of Patient health questionnaire-9 (PHQ-9)8 weeks

Patient health questionnaire-9 has nine questions. Total score ranges from 0 to 27, where higher scores indicate more acute symptoms of depression.

Change from baseline (before using) to week 8 (after 6 weeks of using) of Epworth sleepiness scale (ESS)8 weeks

Epworth sleepiness scale has eight questions. Total score ranges from 0 to 24. A total score of 10 or less is evaluated as normal. A total score of 11 to 15 is evaluated as significant sleepiness. A total score of 16 or more is evaluated as pathological sleepiness.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Total sleep time (TST)8 weeks

Total sleep time is calculated as the total number of minutes that a person actually sleep.

Change from week 1 (before using) to week 8 (after 6 weeks of using) of Number of awakening (NOA)8 weeks

Number of awakening is evaluated as the number of times a person wakes up after falling asleep.

Change from baseline (before using) to week 8 (after 6 weeks of using) of Generalized anxiety disorder-7 item scale (GAD-7)8 weeks

Generalized anxiety disorder-7 item scale has seven questions. Total score ranges from 0 to 21, where higher scores indicate more acute symptoms of anxiety.

Percentage of subjects achieving SE ≥ 85%8 weeks
Compliance (completion rate of lessons, for WELT-IP group only)8 weeks

Compliance is evaluated as completion rate of lessons.

Trial Locations

Locations (1)

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital
🇰🇷Seoul, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.